Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2009-017148-15-IT
EUCTR2009-017148-15-IT
Active, not recruiting
Not Applicable

A retrospective pharmacogenetic analysis of patients with elevated liver enzymes (Hy s law cases or AST/ALT > 10x ULN) in clinical studies CCOX189A0117, CCOX189A2332, CCOX189A2369, CCOX189A0126, CCOX189A0112, CCOX189A0109 or CCOX189A2361 - ND

OVARTIS FARMA0 sites37 target enrollmentApril 23, 2010
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionspatients with elevated liver enzymes (Hy s law cases or AST/ALT > 10x

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
patients with elevated liver enzymes (Hy s law cases or AST/ALT > 10x
Sponsor
OVARTIS FARMA
Enrollment
37
Status
Active, not recruiting
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 23, 2010
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Inclusion criteria Patients eligible for inclusion in this study have to fulfill all of the following criteria: 1\. Patients who received lumiracoxib and experienced a Hy s law or AST/ALT \> 10xULN event after initiating treatment in clinical studies CCOX189A0117, CCOX189A2332, CCOX189A2369, CCOX189A0126, CCOX189A0112, CCOX189A0109 or CCOX189A2361\. 2\. Written informed consent must be obtained before any assessment is performed. Only patients who agree to participate in this pharmacogenetic post\-hoc study by signing the informed consent form will be included in this study.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • •1\. Patients who do not provide written informed consent.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Pharmacogenetic analysis to investigate the association between efficacy and neurotoxicity of oxaliplatin and single nucleotide polymorphismsColorectal cancer
JPRN-UMIN000002490Kyoto University Hospital133
Completed
Not Applicable
Clinical pharmacology and pharmacogenetic study on the clinical response for tamoxifeBreast cancer
JPRN-UMIN000001411Saitama Medical University, Saitama International Medical Center100
Recruiting
Not Applicable
A pharmacogenomics study for adverse effects and clinical outcome to S-1 in gastric cancer patients
JPRN-UMIN000004968Department of Clinical Pharmacology and Genitics, School of Pharmaceutical Science, Univercity of Shizuoka100
Not yet recruiting
Phase 1
The Pharmacogenetic and Pathological Assessment of CYP2C19 Activity in Patients with Advanced CancerAdvanced cancerCancer -
ACTRN12605000393651Cancer Trials New Zealand50
Active, not recruiting
Not Applicable
APPLICATION OF PHARMACOGENOMICS IN THE TREATMENT OF ELDERLY PATIENTS WITH ADVANCED COLORECTAL CANCER - PHARMACOGENOMICS IN THE ELDERLYELDERLY PATIENTS WITH METASTATIC COLORECTAL CANCERMedDRA version: 6.1Level: HLTClassification code 10010040
EUCTR2006-004016-40-ITAZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI